Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00379899
Other study ID # 20060111
Secondary ID
Status Completed
Phase Phase 4
First received September 21, 2006
Last updated July 14, 2014
Start date September 2006
Est. completion date November 2009

Study information

Verified date July 2014
Source Amgen
Contact n/a
Is FDA regulated No
Health authority Australia: Therapeutic Goods AdministrationEuropean Union: European Medicines AgencyUnited States: Food and Drug AdministrationUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate whether cinacalcet + low dose vitamin D attenuates the progression of vascular calcification over one year, compared with a treatment regimen that includes flexible vitamin D dosing in the absence of cinacalcet, in subjects with chronic kidney disease receiving hemodialysis


Recruitment information / eligibility

Status Completed
Enrollment 360
Est. completion date November 2009
Est. primary completion date May 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults with chronic kidney disease receiving hemodialysis.

- Lab tests required at screening include Parathyroid Hormone (PTH), calcium, and phosphorus.

- A screening coronary artery calcification score of at least 30.

Exclusion Criteria:

- Subjects on non-calcium or aluminum containing phosphate binders (example: sevelamer HCl, lanthanum) 30 days prior to screening.

- Subjects on cinacalcet 30 days prior to screening.

- Current or previous use of some osteoporosis medications.

- Started or required change in cholesterol lowering medications within 30 days before screening.

- Abnormal rhythm of the heart.

- Parathyroidectomy done within 3 months prior to screening.

- Anticipated parathyroidectomy or kidney transplant.

- Current intolerance to oral medications, or inability to swallow.

- Unstable medical condition.

- Currently enrolled, or fewer than 30 days have passed since subject used another investigational device or drug.

- Pregnancy or breast feeding.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
cinacalcet
Low dose vitamin D with cinacalcet

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Amgen

References & Publications (5)

Bellasi A, Reiner M, Pétavy F, Goodman W, Floege J, Raggi P. Presence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE study. J Heart Valve Dis. 2013 May;22(3):391-9. — View Citation

Boer R, Lalla AM, Belozeroff V. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J Med Econ. 2012;15(3):509-20. doi: 10.3111/13696998.2012.664799. Epub 2012 Feb 21. — View Citation

Floege J, Raggi P, Block GA, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Chertow GM; ADVANCE Study group. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2010 Jun;25(6):1916-23. doi: 10.1093/ndt/gfp762. Epub 2010 Jan 27. — View Citation

Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J; ADVANCE Study Group. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011 Apr;26(4):1327-39. doi: 10.1093/ndt/gfq725. Epub 2010 Dec 8. — View Citation

Ureña-Torres PA, Floege J, Hawley CM, Pedagogos E, Goodman WG, Pétavy F, Reiner M, Raggi P. Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transplant. 2013 Jan;28(1):146-52. doi: 10.1093/ndt/gfs356. Epub 2012 Sep 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Change From Baseline in CAC Score Percent Change from baseline to week 52 in coronary artery calcification (CAC) score. CAC score ranges from 0 to 7500, with 0 representing no calcification. Baseline and Week 52 No
Secondary Number of Participants Achieving > 15% Progression of CAC. Number of participants achieving >15% progression of coronary artery calcification (CAC) at week 52 52 weeks No
Secondary Absolute Change in PTH Absolute change from baseline in intact Parathyroid Hormone (iPTH) Baseline and Week 52 No
Secondary Change From Baseline in AC Score Change from baseline in aortic calcification (AC) score at week 52. AC score ranges from 0 to >75,000, with 0 representing no calcification. Baseline and Week 52 No
Secondary Change From Baseline of the Progression of AVC. Change from baseline in the aortic valve calcification (AVC) score. AVC score ranges from 0 to >10,000, with 0 representing no calcification. Baseline and Week 52 No
Secondary Percent Change in PTH Percent change from baseline in intact Parathyroid Hormone (iPTH) Baseline and Week 52 No
Secondary Absolute Change in Calcium Absolute change from baseline in serum calcium to weeks 44 through 52 Baseline and Weeks 44 through 52 No
Secondary Percent Change in Calcium Percent change from baseline in corrected serum calcium to weeks 44 through 52 Baseline and Weeks 44 through 52 No
Secondary Absolute Change in Phosphorus Absolute change from baseline in serum phosphorus to weeks 44 through 52 Baseline and Weeks 44 through 52 No
Secondary Percent Change in Phosphorus Percent change from baseline in serum phosphorus to weeks 44 through 52 Baseline and Weeks 44 through 52 No
Secondary Absolute Change in Ca x P Absolute change from baseline in corrected serum calcium x phosphorus to week 44 through week 52 Baseline and Weeks 44 through 52 No
Secondary Percent Change in Ca x P Percent change from baseline in corrected serum calcium x phosphorus (Ca x P) to weeks 44 through 52 Baseline and Weeks 44 through 52 No
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT02502812 - Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects Phase 1
Recruiting NCT04216342 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers Phase 1
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT03646656 - Heart Health Buddies: Peer Support to Decrease CVD Risk N/A
Completed NCT02081066 - Identification of CETP as a Marker of Atherosclerosis N/A
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT03095261 - Incentives in Cardiac Rehabilitation N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Completed NCT02589769 - Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Completed NCT02868710 - Individual Variability to Aerobic Exercise Training N/A
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Recruiting NCT02885792 - Coronary Artery Disease in Patients Suffering From Schizophrenia N/A
Completed NCT02657382 - Mental Stress Ischemia: Biofeedback Study N/A
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Completed NCT02640859 - Investigation of Metabolic Risk in Korean Adults
Completed NCT02272946 - Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk Phase 2
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment